[ad_1]
Medicaid insurance policies fluctuate from state-to-state. With the appearance of recent, GLP-1 medicines (and others) to deal with weight problems and chubby, there are doubtlessly vital well being advantages to be gained. Nevertheless, are State Medicaid Businesses truly protecting these medicines? That is the query requested by Liu et al. (2024). They use information from public state Medicaid formulary and most well-liked drug listing information to find out if a state lined FDA-approved anti-obesity medicines. The variety of reimbursed prescriptions for every antiobesity remedy was recognized from public 2011-2022 Medicaid State Drug Utilization information.
Basically, some however not all anti-obesity medicines are lined. Furthermore, the simpler GLP-1 medicines are sometimes solely lined if they’re used to deal with diabetes (relatively than chubby or weight problems).
Within the first quarter of 2023, 10 of 47 states (21%) with public most well-liked drug lists lined no less than 1 antiobesity remedy; 5 (11%) had unrestricted protection of no less than 1 antiobesity remedy…Individually, 39 states (83%) had unrestricted protection of no less than 1 of the two diabetes variations of GLP-1 RAs.
![Medicaid Protection and Reimbursement of Antiobesity Drugs throughout States – Healthcare Economist Medicaid Protection and Reimbursement of Antiobesity Drugs throughout States – Healthcare Economist](https://www.healthcare-economist.com/wp-content/uploads/2024/03/obesity_meds-1024x524.png)
The complete article is right here.
[ad_2]